Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
https://www.zacks.com/stock/news/2212909/exelixis-exel-reports-positive-eu-patent-ruling-for-cabometyx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212909
Jan 19, 2024 - Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.
0
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
https://www.zacks.com/commentary/2215536/3-generic-drug-stocks-to-watch-amid-improving-market-prospects?cid=CS-ZC-FT-industry_outlook-2215536
Jan 25, 2024 - With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
0
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
https://www.zacks.com/stock/news/2219707/teva-q4-earnings-and-revenues-surpass-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2219707
Feb 01, 2024 - TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
0
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
0
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
0